MedKoo Cat#: 598961 | Name: Lipofectin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lipofectin is a mixture of two cationic lipids, N-[1-(2,3-dioleyloxy)propyl]-n,n,n-trimethylammonium chloride (DOTMA) and dioleoyl phosphotidylethanolamine (DOPE), and has been commonly used to promote transfection of plasmid vectors in vitro and in vivo.

Chemical Structure

Lipofectin
Lipofectin
CAS#128835-92-7

Theoretical Analysis

MedKoo Cat#: 598961

Name: Lipofectin

CAS#: 128835-92-7

Chemical Formula: C83H164ClN2O10P

Exact Mass:

Molecular Weight: 1416.65

Elemental Analysis: C, 70.37; H, 11.67; Cl, 2.50; N, 1.98; O, 11.29; P, 2.19

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Lipofectin;
IUPAC/Chemical Name
1-Propanaminium, N,N,N-trimethyl-2,3-bis(9-octadecenyloxy)-, chloride, (Z,Z)-, mixt. with (Z,Z)-1-((((2-aminoethoxy)hydroxyphosphinyl)oxy)methyl)-1,2-ethanediyl di-9-octadecenoate
InChi Key
MQFKYWPPAXNQCG-OCNHPIIDSA-N
InChi Code
InChI=1S/C42H84NO2.C41H79NO8P.ClH/c1-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-36-38-44-41-42(40-43(3,4)5)45-39-37-35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-2;1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(43)50(38-49-51(46,47)48-36-35-42)37-34-39(41(44)45)32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2;/h20-23,42H,6-19,24-41H2,1-5H3;17-20,39H,3-16,21-38,42H2,1-2H3,(H,44,45)(H,46,47);1H/q+1;;-1/b22-20-,23-21+;19-17-,20-18+;/t42-;39-;/m00./s1
SMILES Code
O=C(O)[C@@H](CCCCCC/C=C/CCCCCCCC)CCO(C(CCCCCCC/C=C\CCCCCCCC)=O)CO[P@@](O)(OCCN)=O.CCCCCCCC/C=C\CCCCCCCCOC[C@@H](OCCCCCCCC/C=C/CCCCCCCC)C[N+](C)(C)C.[ClH-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,416.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pisetsky DS, Reich CF 3rd. The influence of lipofectin on the in vitro stimulation of murine spleen cells by bacterial DNA and plasmid DNA vectors. J Interferon Cytokine Res. 1999 Oct;19(10):1219-26. PubMed PMID: 10547162. 2: Karikó K, Megyeri K, Xiao Q, Barnathan ES. Lipofectin-aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett. 1994 Sep 19;352(1):41-4. PubMed PMID: 7925939. 3: Yeoman LC, Danels YJ, Lynch MJ. Lipofectin enhances cellular uptake of antisense DNA while inhibiting tumor cell growth. Antisense Res Dev. 1992 Spring;2(1):51-9. PubMed PMID: 1422086. 4: Lambert G, Fattal E, Brehier A, Feger J, Couvreur P. Effect of polyisobutylcyanoacrylate nanoparticles and lipofectin loaded with oligonucleotides on cell viability and PKC alpha neosynthesis in HepG2 cells. Biochimie. 1998 Dec;80(12):969-76. PubMed PMID: 9924975. 5: Wu X, Cao C, Kumar VS, Cui W. An innovative technique for inoculating recombinant baculovirus into the silkworm Bombyx mori using lipofectin. Res Microbiol. 2004 Jul-Aug;155(6):462-6. PubMed PMID: 15249063. 6: Mazur W, Ali NM, Grinstead WC, Schulz DG, Raizner AE, French BA. Lipofectin-mediated versus adenovirus-mediated gene transfer in vitro and in vivo: comparison of canine and porcine model systems. Coron Artery Dis. 1994 Sep;5(9):779-86. PubMed PMID: 7858769. 7: Innes CL, Smith PB, Langenbach R, Tindall KR, Boone LR. Cationic liposomes (Lipofectin) mediate retroviral infection in the absence of specific receptors. J Virol. 1990 Feb;64(2):957-61. PubMed PMID: 2153257; PubMed Central PMCID: PMC249198. 8: Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: a microarray study of lipofectin- and oligofectamine-induced gene expression changes in human epithelial cells. J Drug Target. 2003 Jul;11(6):311-23. PubMed PMID: 14668052. 9: Liu D, Wu J. [Experimental observation of foreign gene transfer with lipofectin to the primary human lens epithelial cells]. Zhonghua Yan Ke Za Zhi. 1998 Sep;34(5):349-51, 23. Chinese. PubMed PMID: 11877223. 10: de Fiebre CM, Wu P, Notabartolo D, Millard WJ, Meyer EM. Differential adenoassociated virus vector-driven expression of a neuropeptide Y gene in primary rat brain astroglial cultures after transfection with Sendai virosomes versus Lipofectin. Neurochem Res. 1994 Jun;19(6):643-8. PubMed PMID: 8065520. 11: Zheng G, Zhang JR, Liu FQ, Rao ZG, Wang XW, Zhang XY. [Effects of lipofectin-mediated alpha1,4Gal T antisense oligonucleotide on human glioma cell line SWO-38]. Di Yi Jun Yi Da Xue Xue Bao. 2002 Apr;22(4):299-302. Chinese. PubMed PMID: 12390727. 12: Sawahel WA. The production of transgenic potato plants expressing human alpha-interferon using lipofectin-mediated transformation. Cell Mol Biol Lett. 2002;7(1):19-29. PubMed PMID: 11944047. 13: Rubenstein M, Mirochnik Y, Slobodskoy L, Guinan P. Biotinylation of antisense oligonucleotides does not alter lipofectin enhanced cellular uptake in prostate cancer cell lines. Methods Find Exp Clin Pharmacol. 2001 Nov;23(9):487-90. PubMed PMID: 11876021. 14: Wei ZT, Wang XY, Dong JC, Ma CH, Zhao D, Zhang Y, Sun WS. [Inhibitory effect of endostatin mediated by lipofectin on transplanted ovarian cancer]. Zhonghua Fu Chan Ke Za Zhi. 2005 Jun;40(6):396-9. Chinese. PubMed PMID: 16008891. 15: Okada N, Saito T, Mori K, Masunaga Y, Fujii Y, Fujita J, Fujimoto K, Nakanishi T, Tanaka K, Nakagawa S, Mayumi T, Fujita T, Yamamoto A. Effects of lipofectin-antigen complexes on major histocompatibility complex class I-restricted antigen presentation pathway in murine dendritic cells and on dendritic cell maturation. Biochim Biophys Acta. 2001 Aug 15;1527(3):97-101. PubMed PMID: 11479025. 16: Hill CL, Booth TF, Stuart DI, Mertens PP. Lipofectin increases the specific activity of cypovirus particles for cultured insect cells. J Virol Methods. 1999 Mar;78(1-2):177-89. PubMed PMID: 10204708. 17: Murakawa T, Kajiyama S, Ikeuchi T, Kawakami S, Fukui K. Improvement of transformation efficiency by bioactive-beads-mediated gene transfer using DNA-lipofectin complex as entrapped genetic material. J Biosci Bioeng. 2008 Jan;105(1):77-80. doi: 10.1263/jbb.105.77. PubMed PMID: 18295726. 18: Cao L, Zheng ZC, Zhao YC, Jiang ZH, Liu ZG, Chen SD, Zhou CF, Liu XY. Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Hum Gene Ther. 1995 Nov;6(11):1497-501. PubMed PMID: 8573622. 19: Sugawa N, Ueda S, Nakagawa Y, Nishino H, Nosaka K, Iwashima A, Kurimoto M. An antisense EGFR oligodeoxynucleotide enveloped in Lipofectin induces growth inhibition in human malignant gliomas in vitro. J Neurooncol. 1998 Sep;39(3):237-44. PubMed PMID: 9821109. 20: Ono T, Fujino Y, Tsuchiya T, Tsuda M. Plasmid DNAs directly injected into mouse brain with lipofectin can be incorporated and expressed by brain cells. Neurosci Lett. 1990 Sep 18;117(3):259-63. PubMed PMID: 1710037.